Nouvelle ère thérapeutique dans l’insuffisance cardiaque à fraction d’éjection réduite : quelle population de patients français cela concerne-t-il ?

A new class of cardiovascular drugs, angiotensin receptor neprilysin inhibitors, has shown its efficacy in the PARADIGM-HF study in replacement of renin-angiotensin blockers in symptomatic heart failure patients with reduced ejection fraction, and already treated according to the recommendations. Recent French epidemiological data in the literature allow assessing the number of French patients who could be concerned by the new treatment in taking account the different parameters from the PARADIGM-HF study.